To identify the most effective treatment for NAS, study authors searched various databases for RCTs where a pharmacological agent was used alone or in combination with adjuvant treatments.
From 2007 to 2016, there was an increase in the proportion of substance use treatment facilities offering medication treatment (MT), according to a study published in the January issue of Health Affairs.
The Substance Abuse and Mental Health Services Administration national helpline (800-662-HELP) seems to be underappreciated in the media and by the general population, according to a research letter published online January 14 in JAMA Internal Medicine.
From 1999 to 2017, the drug overdose death rate increased 260 percent among women aged 30 to 64 years.
Secondhand exposure to electronic nicotine delivery systems (ENDS) aerosols may be related to asthma symptoms in youth, according to a new study.
Among persons who inject drugs, 9 cases of wound botulism were identified in Southern California from September 2017 to April 2018, according to research published in the January 4 issue of the US Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Sandoz and Pear Therapeutics announced the launch of reSET-O, a new digital therapeutic for patients aged ≥18 years with opioid use disorder (OUD) currently under clinician care.
From 1999 to 2016, there was close to a threefold increase in the pediatric mortality rate from opioid poisonings in the United States, according to a study published online December 28 in JAMA Network Open.
Currently, naloxone is supplied in ampules and vials for IV, IM or SC administration, in a prefilled auto-injector, and as a nasal spray.
Brixadi utilizes FluidCrystal Injection Depot Technology; once in contact with fluids in the tissue, the solution turns into a nanostructured liquid-crystalline gel allowing for slow release of buprenorphine at a steady rate over 1 week or 1 month.
